Novartis AG vs RTX Corporation: Strategic Comparison

This in-depth comparison examines Novartis AG and RTX Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating RTX Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and RTX Corporation is widest.

On the headline numbers, Novartis AG reports annual revenue of $54.5B against $88.6B for RTX Corporation, while their respective market capitalizations stand at $274.1B and $260.8B. Novartis AG is headquartered in Switzerland and RTX Corporation operates from United States, and those different home markets shape how each company competes.

Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.

RTX Corporation: RTX is less a single product company than an installed-base company. Airlines, airframers, militaries, and allied governments buy platforms that require decades of support, upgrades, spare parts, and sustainment. That lifecycle economics is the center of the model.

Novartis AG and RTX Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and RTX Corporation.

Novartis AG business model: Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.

RTX Corporation business model: RTX makes money from aerospace equipment, commercial and military engines, aftermarket service, spare parts, defense systems, missile programs, radar, sensors, avionics, and long-cycle government contracts. Installed platforms create recurring aftermarket and sustainment revenue for decades.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of RTX Corporation.

Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.

RTX Corporation competitive advantage: RTX is embedded on major aircraft and defense platforms. Once an engine, avionics suite, radar, or missile system is certified, replacing it requires years of testing, procurement, certification, logistics, and political approval. That creates switching costs beyond normal industrial competition.

Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and RTX Corporation each plan to expand from here.

Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.

RTX Corporation growth strategy: RTX growth depends on commercial aerospace aftermarket recovery, GTF engine deliveries and service, Patriot, AMRAAM, Tomahawk, SPY-6, F135 sustainment, international defense demand, and manufacturing capacity expansion.

A closer look at the financial trajectory of Novartis AG and RTX Corporation rounds out the comparison.

Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.

RTX Corporation: RTX reported $88.6 billion in 2025 sales, adjusted EPS of $6.29, operating cash flow of $10.6 billion, and free cash flow of $7.9 billion. Backlog reached $268 billion, including $161 billion commercial and $107 billion defense, giving the company unusually strong revenue visibility.